5-[6-(2-bromo-phenyl)-8-methyl-7-oxo-5,6,7,8-tetrahydro-pyrimido[4,5-d]pyrimidin-2-ylamino]-isoindole-1,3-dione | 686761-21-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 5-[6-(2-bromo-phenyl)-8-methyl-7-oxo-5,6,7,8-tetrahydro-pyrimido[4,5-d]pyrimidin-2-ylamino]-isoindole-1,3-dione
• 英文别名: 5-[[3-(2-bromophenyl)-1-methyl-2-oxo-4H-pyrimido[4,5-d]pyrimidin-7-yl]amino]isoindole-1,3-dione
• CAS: 686761-21-7
• 化学式: C₂₁H₁₅BrN₆O₃
• 分子量: 479.293
• InChiKey: PBMJEJLNNAVPOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Amino-substituted dihydropyrimido[4,5-D]pyrimidinone derivatives
  申请人：——

  公开号：US20040087600A1

  公开（公告）日：2004-05-06

  Compounds of formula I 1 are described. These compounds are protein kinase inhibitors, in particular they inhibit the src family tyrosine kinases. Thus, these compounds are useful for the treatment of diseases mediated by src tyrosine kinases, including cell proliferative disorders such as cancer. Also described are methods of making and using compounds of formula I as well as pharmaceutical compositions containing these compounds.

  描述了化学式I1的化合物。这些化合物是蛋白激酶抑制剂，特别是它们抑制src家族酪氨酸激酶。因此，这些化合物对于治疗由src酪氨酸激酶介导的疾病，包括癌症等细胞增殖性疾病，具有用途。还描述了制备和使用化学式I的化合物的方法，以及含有这些化合物的药物组合物。
• NOVEL AMINO-SUBSTITUTED DIHYDROPYRIMIDO [4,5-D] PYRIMIDIN ONE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1560831A1

  公开（公告）日：2005-08-10
• US7091345B2
  申请人：——

  公开号：US7091345B2

  公开（公告）日：2006-08-15
• [EN] NOVEL AMINO-SUBSTITUTED DIHYDROPYRIMIDO[4,5-D]PYRIMIDINONE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS<br/>[FR] NOUVEAUX DERIVES DE DIHYDROPYRIMIDO[4,5-D]PYRIMIDINONE AMINO-SUBSTITUES, LEUR FABRICATION ET LEUR UTILISATION EN TANT QU'AGENTS PHARMACEUTIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004041823A1

  公开（公告）日：2004-05-21

  The invention describes compounds of the general formula (I), a process for their manufacture, medicaments containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. The said compounds show activity as protein kinase inhibitors, in particular src family tyrosine kinase inhibitors, and may therefore be usefull for the treatment of diseases mediated by said tyrosine kinases.